Canaccord Genuity Remains a Buy on Aptose Biosciences (APTO)

By Jason Carr

Canaccord Genuity analyst John Newman maintained a Buy rating on Aptose Biosciences (APTOResearch Report) yesterday and set a price target of $13.00. The company’s shares closed last Monday at $5.71.

According to TipRanks.com, Newman is a 5-star analyst with an average return of 20.6% and a 44.4% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.

Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $10.29, which is a 72.9% upside from current levels. In a report released yesterday, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.25 and a one-year low of $1.82. Currently, Aptose Biosciences has an average volume of 806.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.